论文部分内容阅读
目的观察替罗非班治疗急性非ST段抬高型心肌梗死的临床效果。方法选取2014年5月-2015年10月医院收治的急性非ST段抬高型心肌梗死患者100例,依照患者意愿分为观察组56例与对照组44例。对照组给予常规药物治疗,观察组在常规治疗的基础上联合替罗非班进行治疗,比较2组治疗效果。结果观察组TIMI血流分级情况明显优于对照组,差异有统计学意义(P<0.05)。观察组治疗后CI、LVEF明显高于对照组,差异有统计学意义(P<0.05)。观察组急性心肌梗死、心血管死亡、再发胸痛、穿刺点出血发生率分别为3.57%、1.79%、1.79%、3.57%均显著低于对照组,差异有统计学意义(P<0.05)。结论替罗非班在急性非ST段抬高型心肌梗死的治疗中疗效显著,不良事件发生率低,值得临床推广应用。
Objective To observe the clinical effect of tirofiban in the treatment of acute non-ST segment elevation myocardial infarction. Methods From May 2014 to October 2015, 100 patients with acute non-ST-segment elevation myocardial infarction admitted to the hospital were divided into observation group (56 cases) and control group (44 cases) according to patients’ wishes. The control group was given conventional drug treatment. The observation group was treated with tirofiban on the basis of routine treatment, and the treatment effect was compared between the two groups. Results TIMI grade in the observation group was significantly better than that in the control group, the difference was statistically significant (P <0.05). After treatment, CI and LVEF in observation group were significantly higher than those in control group (P <0.05). The incidences of acute myocardial infarction, cardiovascular death, recurrent chest pain and puncture point in the observation group were 3.57%, 1.79%, 1.79% and 3.57%, respectively, which were significantly lower than those in the control group (P <0.05). Conclusion Tirofiban has a significant effect in the treatment of acute non-ST segment elevation myocardial infarction with a low incidence of adverse events, which deserves clinical application.